End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
103,600 KRW | +0.48% | -0.67% | -20.86% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company has a low valuation given the cash flows generated by its activity.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is not the most generous with respect to shareholders' compensation.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.86% | 967M | - | ||
+19.10% | 43.74B | B- | ||
+21.99% | 22.26B | B+ | ||
+16.41% | 14.9B | - | ||
+8.84% | 13.39B | B+ | ||
+40.94% | 12.12B | B | ||
-9.64% | 6.92B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+12.41% | 5.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A185750 Stock
- Ratings Chong Kun Dang Pharmaceutical Corp.